Key result
Adolescents evaluated shortly after cancer treatment had a significantly higher prevalence of cumulating ≥2 cardiometabolic complications compared to children (42% vs. 2%; P<0.001).
Why the study?
This study aimed to compare the cardiometabolic health of children and adolescents and identify factors associated with cardiometabolic complications shortly after cancer treatment.
Are adolescents more affected by cardiometabolic complications than children shortly after pediatric cancer treatment?
Cross-Sectional (n=80)
Are adolescents more affected by cardiometabolic complications than children shortly after pediatric cancer treatment?
Adolescents exhibit a significantly worse cardiometabolic profile than children shortly after completing pediatric cancer therapy, highlighting the need for targeted early interventions.
May support age-specific cardiometabolic monitoring in adolescents post-cancer therapy; cross-sectional data leave this hypothesis-generating for longitudinal studies.
This cross-sectional study aimed at comparing the cardiometabolic (CM) health of children and adolescents and identifying factors associated with CM complications shortly after cancer treatment. Cancer-related characteristics, blood pressure (BP), anthropometry, and biochemical parameters were collected in 80 patients (56.3% female, mean age: 11.8 years; range: 4.5 − 21.0) a mean of 1.4 years following therapy completion. Compared to children, adolescents had higher mean z-score of insulin (–0.47 vs. 0.20; P = 0.01), HOMA-IR (–0.40 vs. 0.25; P = 0.02), waist-to-height ratio (0.36 vs. 0.84; P = 0.01), subscapular skinfold thickness (–0.19 vs. 0.47; P = 0.02), total body fat (–1.43 vs. 0.26; P < 0.01), and lower mean z-score of HDL-C (0.07 vs. –0.53; P < 0.01). Adolescents were more likely to have high BP (42% vs. 15%; P < 0.01), dyslipidemia (64% vs. 15%; P < 0.001), and cumulating ≥ 2 CM complications (42% vs. 2%; P < 0.001) than children. Adiposity indices (z-scores) were associated with high BP [odds ratio (OR) ranging from 2.11 to 4.09] and dyslipidemia (OR ranging from 2.06 to 4.34). These results suggest that adolescents have a worse CM profile than children shortly after therapy and that adiposity parameters are associated with CM complications, highliting the importance to develop intervention strategies targeting this population.
No takes yet. Share an insight, caveat, or question.
Bélanger et al. (2022) conducted a cross-sectional in Pediatric cancer (n=80). Adolescent age vs. Childhood age was evaluated on Cumulating ≥ 2 cardiometabolic complications (p=<0.001). Adolescents evaluated shortly after cancer treatment had a significantly higher prevalence of cumulating ≥2 cardiometabolic complications compared to children (42% vs. 2%; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: